Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 306)

NCT03566823 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
34
Enrollment
INDUSTRY
Sponsor class

Stopped Sponsor decision to discontinue the SHP647 (ontamalimab) clinical trial development program for inflammatory bowel diseases (IBD) early.

Conditions

Interventions

Sponsor

Shire